Bupropion/zonisamide
Combination of
BupropionNorepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
ZonisamideSulfonamide anticonvulsant
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
  (verify)

Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity.[1][2][3] Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor.[1] The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.[1][4][5]

See also

References

  1. 1 2 3 "Bupropion/Zonisamide - AdisInsight".
  2. ↑ "Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half". Archived from the original on 2010-01-11. Retrieved 2010-01-07.
  3. ↑ Empatic Obesity Drug Information and News
  4. ↑ Ioannides-Demos LL, Piccenna L, McNeil JJ (2011). "Pharmacotherapies for obesity: past, current, and future therapies" (PDF). Journal of Obesity. 2011: 179674. doi:10.1155/2011/179674. PMC 3006492. PMID 21197148.
  5. ↑ Adan RA (February 2013). "Mechanisms underlying current and future anti-obesity drugs". Trends in Neurosciences. 36 (2): 133–40. doi:10.1016/j.tins.2012.12.001. PMID 23312373. S2CID 21974224.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.